These data were collected from a real-world setting at a cancer center in Romania, where the impact of CDK4/6i therapy was evaluated across various variables, including treatment type, hormonal therapy combination, age, histological grade, and presence of metastases. The gene discussed is CDK4; the disease is cancer.